Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Nov 14, 2022 7:29pm
178 Views
Post# 35098355

RE:Timing of Phase III for Panc

RE:Timing of Phase III for Panc

Thanks. That does help. Good information.

My question to that would be as the original standard Phase II trail was completed back in 2014-2016, some of that process would have already been started and in place. i would assume.

I assume the 'Special Protocal' letter and letter of favour, came from that process back in around 2016.

The other side trials IND, AWARE-1 and BRACELET-1 were only additional information building upon the original standard Phase II trail and Phase III trail application.

So my question would be, do those side trails still require the 90 days? Or, would/could their data just be added into the original Phase II trail final documents and request for a Phase III trial, as those side trails were only building on the previous Phase IIi application documents that are already in the FDA process?

I have no idea, but if the FDA already started that process back in 2016, does that cut those time lines?
 

I would think that with the porceess started in 2016, they FDA might be able to expidite that procees under the original Phase III application  ptha5 occurred around 2016???
Purely speculation there.


I have no idea ... thanks for the note. That would helps to suggest potentail time lines.

<< Previous
Bullboard Posts
Next >>